NCT03490669 - Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

September 23, 2019

Study Completion Date

September 23, 2019

Conditions

Advanced Solid TumorsPancreatic CancerNon Small Cell Lung CancerOvarian Cancer

Interventions

BIOLOGICAL

MSC-1

humanized monoclonal antibody for intravenous administration

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Cancer Center- Westchester, Harrison

START MidWest, Grand Rapids

HonorHealth, Scottsdale

Memorial Sloan Kettering Cancer Center- Monmouth, Middletown

Princess Margaret Cancer Center, Toronto

Hospital Universitario Vall d'Hebron, Barcelona